REFERENCES
- PaleIla FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853–860.
- Youle M. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother 2007;60(6):1195–1205.
- King JR, Wynn H, Brundage R, Acosta EP. Pharmacoki-netic enhancement of protease inhibitor therapy. Clin Pharmacokinet. 2004;43(5):291–310.
- FDA. CDER. Reyataz (online). Available at: http://www.fda.gov/cdertfoi/labe1/2006/021567s007Ib1.pdf. Accessed July 2008.
- Squires K, Lazzarin A, Gatell J, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004;36(5)1 011–1019.
- Molina JM, Andrade-Villanueva J, Echevarria J, et al. Efficacy and safety of once-daily atazanavir/ritonavir compared to twice-daily lopinavir/ritonavir, each in combi-nation with tenofovir and emtricitabine in ARV-naive HIV-1-infected subjects: the CASTLE study, 48-week results. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; 2008; Boston, MA. Abstract 37.
- Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active anti-retroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008;47(2):161–167.
- Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral ther-apy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (A1424-097) 48-week results. Clin Infect Dis. 2007;44(11):1484–1492.
- Kivexa, INN-abacavir/lamivudine (online). Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Kivexa/H-581-Pl-es.pdf. Accessed July 2008.
- Gonzalez de Requena D, Bonora S, Canta F, et al. Ata-zanavir Ctrough is associated with efficacy and safety: definition of therapeutic range. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston, MA. Abstract 645.
- Mallal S, Phillips E, Carosi G, et al. HLA-B"5701 screen-ing for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568–579.
- Poirier JM, Guiard-Schmid J, Meynard J, et al. Atazana-vir (ATV) plasma concentrations in HIV-infected patients treated with 400 mg ATV or ritonavir boosted ATV (300/100 mg) qd in clinical practice. In: Program and abstracts of the 7th International Workshop on Clinical Pharmacology of HIV Therapy; 2006; Lisbon. Abstract 11.
- Moltó J, Santos JR, Valle M, et al. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Ther Drug Montt. 2007;29(5):648–651.
- Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Op/n. 2005;21(10):1683–1692.
- Fulco PP, Vora UB, Bearman GM. Acid suppressive therapy and the effects on protease inhibitors (CE). Ann Pharmacother. 2006;40 (11):1974–1983.
- Bertz R, Wang Y, Manhke L, et al. Assessment of phar-macokinetic/pharmacodynamic relationships through 48 weeks from a study in HIV+ ARV-naive subjects receiv-ing antiretroviral regimens containing atazanavir 400 mg or atazanavir/ritonavir 300/100 mg once daily. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles. Abstract 565.